0000000000154304

AUTHOR

Rocío Aller

showing 6 related works from this author

Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: Time for reappraisal of BMI-driven approach?

2021

[Objective] The full phenotypic expression of non-alcoholic fatty liver disease (NAFLD) in lean subjects is incompletely characterised. We aimed to investigate prevalence, characteristics and long-term prognosis of Caucasian lean subjects with NAFLD.

MaleDiseaseBody Mass IndexCohort StudiesLiver disease0302 clinical medicineNon-alcoholic Fatty Liver DiseaseAdult Body Mass Index Cohort Studies Fatty liver Female Humans Male Middle Aged Non-alcoholic Fatty Liver Disease Non-alcoholic steatohepatitis Prognosis Survival Rate Thinness Whitesnonalcoholic steatohepatitis2. Zero hunger0303 health sciencesFatty liverNASHGastroenterologyMiddle AgedPrognosis3. Good healthSurvival RateCohort030211 gastroenterology & hepatologyFemalemedicine.symptomAdultmedicine.medical_specialtySettore MED/12 - GASTROENTEROLOGIAdigestive systemWhite People03 medical and health sciencesThinnessNAFLDInternal medicinemedicineHumansPNPLA3030304 developmental biologyfatty liverbusiness.industryWhitesSettore MED/09 - MEDICINA INTERNAnutritional and metabolic diseasesmedicine.diseaseLean-NASHObesitydigestive system diseasesLean-OutcomesSteatohepatitisbusinessWeight gainBody mass index
researchProduct

Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease.

2020

Metabolic associated fatty liver disease (MAFLD) is the most prevalent liver disease in Western nations, with high heritability. A recent study of Japanese patients with the disease suggested that TLL1 rs17047200 is associated with fibrosis; whether a similar association is observed in Caucasian patients with MAFLD is unknown. We investigated the association of the TLL1 rs17047200 polymorphism with liver fibrosis in a cohort of Caucasian patients with MAFLD (n = 728). We also investigated whether TLL1 expression is altered during liver injury in humans, in murine models of fibrosis, and in in-vitro. While TLL1 expression is upregulated in the liver of humans with MAFLD and in mice, the rs17…

Liver CirrhosisMaleSteatosisGene ExpressionDiseasePathology and Laboratory MedicineInbred C57BLGastroenterologyPathogenesisCytopathologyCohort StudiesLiver diseaseMice0302 clinical medicineFibrosisMedicine and Health SciencesLiver injury0303 health sciencesMultidisciplinaryLiver DiseasesQFatty liverRTLL1Single NucleotideMiddle Aged3. Good healthUp-RegulationAdult; Animals; Cohort Studies; Fatty Liver; Female; Genetic Variation; Humans; Liver Cirrhosis; Male; Mice; Mice Inbred C57BL; Middle Aged; Tolloid-Like Metalloproteinases; Up-Regulation; Polymorphism Single NucleotideMedicineLiver Fibrosis030211 gastroenterology & hepatologyFemaleAnatomyResearch ArticleAdultmedicine.medical_specialtyHistologyTolloid-Like MetalloproteinasesSettore MED/12 - GASTROENTEROLOGIAScienceGastroenterology and HepatologyPolymorphism Single Nucleotide03 medical and health sciencesInternal medicinemedicineGeneticsAnimalsHumansPolymorphism030304 developmental biologyNutritionbusiness.industryAdult Animals Cohort Studies Fatty Liver Female Genetic Variation Humans Liver Cirrhosis Male Mice Mice Inbred C57BL Middle Aged Tolloid-Like Metalloproteinases Up-Regulation Polymorphism Single NucleotideBiology and Life SciencesGenetic Variationmedicine.diseaseFibrosisDietFatty LiverMice Inbred C57BLn/aAnatomical PathologySteatosisbusinessDevelopmental Biology
researchProduct

Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease W…

2020

HEPAmet Registry.

AdultLiver CirrhosisMalemedicine.medical_specialtySteatosis[SDV]Life Sciences [q-bio]BiopsyLikelihood ratios in diagnostic testingGastroenterologySeverity of Illness IndexDecision Support Techniques03 medical and health sciences0302 clinical medicineFibrosisNon-alcoholic Fatty Liver DiseasePositive predicative valueInternal medicineNonalcoholic fatty liver diseaseHOMAMedicineHumansComputingMilieux_MISCELLANEOUSAged2. Zero hungerNASH FIBROSISHepatologymedicine.diagnostic_testReceiver operating characteristicbusiness.industryPrognostic FactorGastroenterologyOdds ratioMiddle Agedmedicine.diseasePrognosis3. Good healthCross-Sectional StudiesDiagnostic ToolCirrhosisLiver030220 oncology & carcinogenesisLiver biopsyDiagnostic odds ratio030211 gastroenterology & hepatologyFemalebusinessClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
researchProduct

Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 Locus.

2021

This article also appears in: Health, Medical, and Life Sciences Virtual Issue for Advanced Science.

FGF21General Chemical EngineeringGeneral Physics and AstronomyMedicine (miscellaneous)CODON USAGE BIAS02 engineering and technology01 natural sciencesGLUCOSEACTIVATIONPF-05231023ComputingMilieux_COMPUTERSANDEDUCATIONGeneral Materials SciencegeneticsCells CulturedINSULIN-RESISTANCEFull PaperFatty liverQGeneral Engineeringfibroblast growth factor 21 genetics metabolic metabolic associated fatty liver disease Cells Cultured Enzyme-Linked Immunosorbent Assay Fatty Liver Fibroblast Growth Factors Humans Inflammation LiverFull Papers021001 nanoscience & nanotechnologyPhenotype3. Good healthLiverOBESITY221 Nano-technology0210 nano-technologyReprogrammingEXPRESSIONmedicine.medical_specialtySettore MED/12 - GASTROENTEROLOGIAScienceEnzyme-Linked Immunosorbent Assayfibroblast growth factor 21Biology010402 general chemistryBiochemistry Genetics and Molecular Biology (miscellaneous)metabolic associated fatty liver diseaseInsulin resistancemetabolicInternal medicinemedicineHumansSecretionFGF21 RESISTANCEAlleleInflammationmedicine.disease0104 chemical sciencesFatty LiverFibroblast Growth FactorsEndocrinologyRNA SECONDARY STRUCTURETRANSLATIONHormoneAdvanced science (Weinheim, Baden-Wurttemberg, Germany)
researchProduct

Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease.

2021

[Background & Aims] Non-invasive scoring systems (NSS) are used to identify patients with non-alcoholic fatty liver disease (NAFLD) who are at risk of advanced fibrosis, but their reliability in predicting long-term outcomes for hepatic/extrahepatic complications or death and their concordance in cross-sectional and longitudinal risk stratification remain uncertain.

0301 basic medicineAdultMalemedicine.medical_specialtyCirrhosisConcordanceSettore MED/12 - GASTROENTEROLOGIAHFSDiseaseBARDGastroenterologySeverity of Illness IndexTime03 medical and health sciences0302 clinical medicineFibrosisNon-alcoholic Fatty Liver DiseasePredictive Value of TestsInternal medicineNFSmedicineHumansIn patientAPRINSSHepatologybusiness.industryFatty liverNASHReproducibility of ResultsMiddle Agedmedicine.diseasePrognosisAPRI BARD FIB-4 HFS NASH NFS NSS Adult Area Under Curve Cross-Sectional Studies Female Humans Liver MaleMiddle Aged Non-alcoholic Fatty Liver DiseasePrognosis ROC CurveReproducibility of Results Research Design Severity of Illness Index Predictive Value of Tests Time030104 developmental biologyCross-Sectional StudiesLiverROC CurveResearch DesignArea Under CurveCohortAPRI; BARD; FIB-4; HFS; NASH; NFS; NSSFIB-4030211 gastroenterology & hepatologyFemalebusinessLiver cancerJournal of hepatology
researchProduct

Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis : A longitudinal study of 1893 biopsy-proven no…

2021

[Background and Aim] Histological score systems may not fully capture the essential nonalcoholic steatohepatitis (NASH) features, which is one of the leading causes of screening failure in clinical trials. We assessed the NASH distribution and its components across the fibrosis stages and their impact on the prognosis and their relationship with the concept of metabolic-associated fatty liver disease (MAFLD).

Liver Cirrhosismedicine.medical_specialtyCirrhosisSteatosisBiopsyGastroenterologydigestive systemBallooning03 medical and health sciencesLiver disease0302 clinical medicineNon-alcoholic Fatty Liver DiseaseFatty liver diseaseInternal medicineBiopsyNonalcoholic fatty liver diseasemedicineassociated fatty liver diseaseMetabolic-associated fatty liver diseaseHumansmetabolic&#8208Longitudinal StudiesFirst episodeInflammationHepatologymedicine.diagnostic_testballooning fatty liver disease inflammation metabolic-associated fatty liver disease natural coursesteatohepatitis steatosisbusiness.industryFatty liverNatural coursesteatohepatitismedicine.diseasedigestive system diseasesLiver030220 oncology & carcinogenesis030211 gastroenterology & hepatologySteatosisSteatohepatitisbusiness
researchProduct